PET-CT SCANNER DEVICE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

PET-CT Scanner Device Market Analysis & Forecast: 2026-2033

The Global PET-CT Scanner Device Market is estimated to be valued at USD 2.60 Bn in 2026 and is expected to reach USD 3.99 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2026 to 2033.

Key Takeaways

• By Product Type, the stationary PET-CT scanners segment is projected to dominate the global PET-CT scanner device market with a 60.7% share in 2026.
• By Region, North America is anticipated to retain its leadership position in the global PET-CT scanner device market with a 39.2% revenue share in 2026.

Market Overview

The global PET-CT Scanner Device Market is experiencing steady growth, driven by rising cancer prevalence, expanding applications in neurology and cardiology, and growing demand for precise diagnostic imaging. Technological advancements in full-ring detector systems and hybrid imaging capabilities are enhancing clinical accuracy and efficiency. Widespread adoption of stationary PET-CT scanners in hospitals and diagnostic centres supports market expansion.

Current Events and Its Impact

Pricing Analysis on the PET-CT Scanner Device Market

The pricing of PET-CT scanner devices varies significantly depending on factors such as scanner type (stationary vs. mobile), detector configuration (full-ring vs. partial-ring), brand reputation, and regional procurement dynamics.

 High-end stationary PET-CT scanners with full-ring detectors and AI-powered imaging software can range from $1.5 million to $2.5 million per unit, particularly in high-income countries with advanced healthcare systems. In contrast, mobile and entry-level models may range from $800,000 to $1.2 million, offering affordability with basic diagnostic capabilities.

In regions like North America and Europe, procurement is often centralized through public tenders or bulk purchases by hospital networks, enabling negotiated pricing and service agreements. Meanwhile, emerging markets in Asia Pacific and LAMEA benefit from cost-optimized models, local manufacturing, and public-private financing initiatives.

Maintenance, software upgrades, and scanner downtime also influence the total cost of ownership. As AI integration and software-as-a-service (SaaS) models rise, pricing is increasingly bundled with subscription-based image processing solutions.

Role Of Emerging Technology PET-CT Scanner Device Market

Emerging technologies are playing a transformative role in the PET-CT scanner device market, driving improvements in diagnostic accuracy, operational efficiency, and patient outcomes. The integration of artificial intelligence (AI) and machine learning algorithms enables automated image reconstruction, faster scan times, and enhanced detection of anomalies, particularly in oncology and neurology. These advancements reduce radiologist workload and support early, precise diagnoses.

Additionally, next-generation digital detectors and time-of-flight (TOF) technology offer higher spatial resolution and sensitivity, allowing for reduced tracer doses and improved image quality. Cloud-based platforms are further revolutionizing data management by enabling remote access, teleconsultation, and real-time collaboration across healthcare networks.

Hybrid modalities that combine PET-CT with other imaging tools (like MRI) are also gaining traction for multi-dimensional analysis. As these innovations become more accessible, they are expanding PET-CT adoption beyond high-income countries and into emerging markets, thereby democratizing access to advanced diagnostic imaging and driving overall market growth.

Market Concentration and Competitive Landscape

PET-CT Scanner Device Market Trends

•   Rising incidence and prevalence of cancer

Cancer has been one of the major public health concerns across the world. The incidence and prevalence of various cancer types has seen a consistent rise over the past few decades. As per various global health reports, the number of new cancer cases diagnosed each year is expected to rise from 18.1 million in 2018 to 29.5 million by 2040.

While improvements in cancer screening and diagnostics have contributed to the rise in incidence rates, other factors like changing lifestyle patterns, growing elderly population, and environmental pollutants are also considered to be driving the steady increase in cancer burden globally.

PET-CT scanners have emerged as an important diagnostic tool for detecting, diagnosing, staging and restaging of various cancers. It helps in visualization and characterization of tumours in the body with high sensitivity and specificity. The scanner is able to detect even small cancer lesions and help determine the extent or spread of disease which has significant implications on further treatment strategies.

With rising cancer prevalence, there is greater focus on early and accurate diagnosis to commence appropriate treatment at earliest. PET-CT's ability to detect most cancers including lung cancer, colorectal cancer, lymphoma, and melanomas at microscopic level without invasive procedures make it a preferred choice. It provides valuable whole-body assessment and helps clinician take informed decisions regarding the stage of cancer and treatment approach.

The increasing trend of cancers would continue to drive demand for advanced diagnostic modalities like PET-CT scanners. As more number of individuals are diagnosed with cancer types every year, effective diagnosis and monitoring becomes crucial.

In October 2024, The Medical Dive reported that GE HealthCare received FDA clearance for Flyrcado (flurpiridaz F‑18)—a new radiotracer designed to improve cardiac PET imaging, especially for patients with high BMI and women potentially increasing PET‑CT adoption in cardiovascular diagnostics.

• Increasing Demand for Accurate and Non-invasive Diagnostic Techniques

Diagnostic imaging has advanced significantly over the past few decades. Conventional imaging procedures like X-ray, CT, MRI, and ultrasound while useful have certain limitations. There was a need for diagnostic modalities which can better characterize tumours, detect abnormalities at molecular level with high sensitivity, and also be minimally invasive. This increasing demand led to the emergence and rapid adoption of PET-CT technology across healthcare facilities globally.

PET imaging using radioactive tracers overcomes limitations of anatomical imaging alone. It provides invaluable functional and molecular information about abnormal metabolic activity within the body. When combined with CT, it offers precise anatomical localization of functional abnormalities detected. This multi-parametric approach revolutionized disease diagnosis and management. PET-CT is found highly valuable not just for oncology but also for cardiology, neurology, and several other clinical applications.

With growing awareness, patients and healthcare providers increasingly prefer accurate, non-invasive procedures for evaluation and surveillance of diseases. Procedures requiring tissue biopsy are being avoided if comparable or better precision can be obtained non-invasively. PET-CT perfectly fits this need as it does not require the removal of any tissue samples. It captures whole-body functional and metabolic activity related pictures within a single session without any need for surgery. This has made it very attractive for repeat scans essential for treatment monitoring and response assessment.

In April 2025, Reuters (via TradingView) reported that Positron Corporation secured a deal to sell four PET‑CT scanners to a leading cardiovascular diagnostics provider—highlighting growing demand for advanced PET imaging in cardiology and strengthening Positron’s position in the molecular imaging sector.

Opportunities in the PET-CT Scanner Device Market

• Emerging Markets in Asia Pacific and Latin America

One of the key opportunities for the global PET-CT scanner device market lies in the emerging economies of Asia Pacific and Latin America regions. Both regions have witnessed strong economic growth over the past decade and growing healthcare budgets. The rising healthcare spending has also led to increasing investments towards upgrading medical imaging infrastructure in these developing nations. This presents a lucrative potential market for PET-CT scanner device manufacturers.

Many countries like India, China, Brazil, and Mexico now have growing middle-class populations who can afford advanced treatments. In addition, governments are also providing more support to modernize diagnostic capabilities. If manufacturers effectively target these emerging regions, it can help compensate the market to an extent and drive future revenue streams for sustained growth of the PET-CT scanner device industry worldwide. Proactive entry into such fast developing markets at an early stage can enable companies to gain a stronger foothold.

Segmental Insights

PET-CT Scanner Device Market Insights, By Product Type

The stationary PET-CT scanners segment is projected to dominate the global PET-CT scanner device market with a 60.7% share in 2026. This dominance is supported by well-established infrastructure in hospitals and diagnostic centres, which prefer stationary units for their high image accuracy, ease of integration, and consistent patient throughput. Their widespread usage in cancer, neurology, and cardiology diagnostics reinforces their stronghold in clinical imaging workflows.

PET-CT Scanner Device Market Insights, By Detector Type

Full-ring PET-CT scanners are expected to account for the largest detector type share in 2026, driven by their superior spatial resolution, faster acquisition times, and enhanced image quality. These advantages make them the preferred choice in high-end diagnostic applications, enabling earlier and more accurate disease detection, especially in oncology and neurology. As precision imaging becomes more critical, full-ring systems are becoming integral to advanced diagnostic settings.

PET-CT Scanner Device Market Insights, By Application

The oncology segment is forecasted to contribute the highest application share in the PET-CT scanner device market by 2026. The growing prevalence of cancer, along with PET-CT’s vital role in staging, treatment planning, and monitoring therapeutic response, underpins this growth. Increasing integration of PET-CT into multidisciplinary cancer care supports higher adoption across regions, with oncologists relying heavily on its detailed metabolic imaging for personalized therapy decisions.

Regional Insights

North America PET-CT Scanner Device Market Trends and Analysis

North America is anticipated to retain its leadership position in the global PET-CT scanner device market with a 39.2% revenue share in 2026. This dominance is attributed to the region’s advanced healthcare infrastructure, growing demand for diagnostic imaging, and well-established reimbursement frameworks.

The presence of major imaging technology providers and consistent clinical innovations especially in oncology and neurology reinforce North America’s stronghold. Ongoing investments in AI-powered diagnostic tools and hybrid imaging further support regional growth.

Europe PET-CT Scanner Device Market Trends and Analysis

Europe holds a significant position in the global PET-CT scanner device market, driven by its universal healthcare systems, increasing geriatric population, and proactive screening programs. Countries like Germany, France, and the United Kingdom are prioritizing early cancer detection and neurodegenerative disease diagnosis, fuelling the adoption of PET-CT systems.

Supportive government funding, collaborative research projects, and the emphasis on precision diagnostics continue to drive technology integration and adoption across both public and private healthcare institutions.

PET-CT Scanner Device Market Dominating Countries

United States and Canada

The United States remains the dominant force in the PET-CT scanner device market, underpinned by a sophisticated healthcare infrastructure, strong reimbursement ecosystem, and early adoption of advanced diagnostic technologies. With leading manufacturers such as GE Healthcare and Siemens Healthineers operating in the region, innovation and availability of next-generation PET-CT systems are robust. The integration of AI and advanced image processing software continues to enhance oncology and neurology diagnostics, reinforcing the U.S.’s leadership in clinical imaging.

Canada, while smaller in scale, contributes significantly through its publicly funded healthcare system and high per capita imaging utilization. The country’s investment in early cancer detection programs and collaboration with global OEMs ensures steady demand for PET-CT systems, particularly in urban medical centres and research facilities.

Market Report Scope

PET-CT Scanner Device Market Report Coverage

Analyst Viewpoint – PET-CT Scanner Device Market

• Analysts hold an optimistic view of the global PET-CT scanner device market, driven by rising cancer incidence, increasing adoption of hybrid imaging, and the growing demand for precision diagnostics. The expanding clinical utility of PET-CT in oncology, cardiology, and neurology, along with government support for early disease detection programs, is contributing to sustained market expansion across both developed and emerging economies.
• Emerging technologies are reshaping market dynamics. Analysts point to the integration of artificial intelligence (AI) and advanced image processing software as key enablers of faster, more accurate diagnoses and improved workflow efficiency. The development of digital PET technology and time-of-flight (TOF) imaging is further enhancing spatial resolution and reducing scan time and tracer dose requirements.
• North America remains the market leader, supported by advanced healthcare infrastructure and reimbursement systems. However, analysts highlight Asia Pacific—particularly China and India—as high-growth regions, spurred by rising healthcare investments, infrastructure 

PET-CT Scanner Device Market: Key Development

• In June, 2025, GE HealthCare and Stanford Medicine deepened their partnership to advance total‑body PET‑CT technology, focusing on ultra-fast, low-dose imaging and multi‑organ assessment. This innovation accelerates next-gen PET‑CT adoption by enhancing diagnostic capabilities, speeding scan times, and improving patient comfort benefiting especially pediatric and theranostic applications.
• In May 2025, a market report highlighted growing deployment of AI-driven image analysis in digital PET‑CT devices to improve diagnostic accuracy and differentiate modalities like total‑body PET-CT. The rise of AI-enabled PET‑CT systems fosters faster interpretations, lesion quantification, and operational efficiency, stimulating demand for upgraded, smarter imaging platforms.
• In March, 2025 The FDA cleared Gozellix (Ga-68 gozetotide kit) for PSMA PET imaging of prostate cancer, offering extended shelf-life and distribution flexibility. Broader availability of this tracer enhances PET‑CT utilization in oncology, pushing demand for compatible scanners and supporting expanded clinical workflows.
• In July, 2024, Positrigo received FDA 510(k) clearance for NeuroLF, an ultra-compact, seated-position brain PET scanner. This device broadens PET accessibility for neurology applications, particularly dementia and epilepsy monitoring, enabling use in smaller clinics and specialty centres.
• In June 2024, A 510(k) clearance was granted for the Biograph Trinion PET‑CT system, featuring air-cooled digital detectors, enhanced time-of-flight, and energy-saving modes. Its compact, energy-efficient design with versatile clinical capabilities supports adoption in varied hospital settings, reducing operational costs and fostering eco-friendly imaging practices.

Market Segmentation

• By Product Type Insights (Revenue, USD Bn, 2021 - 2033)
• • Stationary PET-CT Scanners
  • Portable/Mobile PET-CT Scanners
• By Detector Type Insights (Revenue, USD Bn, 2021 - 2033)
• • Full-Ring PET-CT Scanners
  • Partial-Ring PET-CT Scanners
• By Application Insights (Revenue, USD Bn, 2021 - 2033)
• • Oncology
  • Cardiology
  • Neurology
  • Others (Infection Imaging, etc.)
• By End User Insights (Revenue, USD Bn, 2021 - 2033)
• • Hospitals
  • Diagnostic Imaging Centers
  • Academic and Research Institutions
  • Ambulatory Surgical Centers,
  • Others (Private Clinics, etc.)
• By Modality Insights (Revenue, USD Bn, 2021 - 2033)
• • Hybrid PET-CT Scanners
  • Standalone PET Scanners
  • Standalone CT Scanners
• By Regional Insights (Revenue, USD Bn 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • General Electric Co.
  • Siemens Healthineers
  • Koninklijke Philips N.V.
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Mediso Ltd.
  • PerkinElmer, Inc.
  • Toshiba Corporation
  • Bruker Corporation
  • Neusoft Medical Systems
  • Yangzhou Kindsway Biotech Co. Ltd.
  • Shimadzu Corporation
  • United Imaging
  • Positron Corporation
  • MIE (Medical Imaging Electronics)
  • Basda
  • MinFound Medical Systems
  • Radimage Technologies Pvt. Ltd.
  • Edge Medical Solutions Pvt. Ltd.
  • GS Medical Imaging Private Limited

Sources

The Stakeholders Consulted

• Radiologists and nuclear medicine specialists
• Hospital procurement managers and imaging center administrators
• PET-CT scanner manufacturers and component suppliers
• Healthcare equipment distributors and service providers
• Clinical researchers and oncologists
• Regulatory and compliance experts in diagnostic imaging
• Health ministry officials and public healthcare system planners
• Private diagnostic lab operators and healthcare IT integrators

Databases Opened

• U.S. Food and Drug Administration (FDA) – 510(k) and PMA Medical Device Database
• Centers for Medicare & Medicaid Services (CMS) – Diagnostic Imaging Reimbursement Data
• Ministry of Health and Family Welfare (India) – National Health Systems Resource Centre Data
• WHO Global Health Observatory (GHO) – Diagnostic Imaging Statistics

Magazines & Trade Publications

• Diagnostic Imaging Magazine
• Radiology Today
• Imaging Technology News (ITN)
• Medical Device and Diagnostic Industry (MD+DI)
• HealthCare Business News

Scientific and Industry Journals

• Journal of Nuclear Medicine
• European Journal of Radiology
• PET Clinics
• American Journal of Roentgenology (AJR)
• Radiology (RSNA Journal)

Newspapers & Media Outlets

• The Wall Street Journal – Health Technology Section
• Bloomberg – Healthcare Innovation News
• Reuters – Medical Devices and Imaging Industry Updates
• The Economic Times – Healthcare and Diagnostics Coverage
• Business Standard – MedTech and Hospital Infrastructure

Associations and Regulatory Bodies

• Radiological Society of North America (RSNA)
• Society of Nuclear Medicine and Molecular Imaging (SNMMI)
• U.S. Food and Drug Administration (FDA) – Medical Imaging Devices Division
• European Medicines Agency (EMA) – Medical Device Regulations
• Atomic Energy Regulatory Board (AERB), India – Nuclear Medicine Guidelines

Public Domain Sources

• World Health Organization (WHO) – Diagnostic Imaging Reports
• European Commission – Health Technology and Imaging Strategy Reports
• Centers for Disease Control and Prevention (CDC) – Cancer and Imaging Data
• OECD Health Statistics – Medical Imaging Infrastructure

Proprietary Research Elements

• CMI Data Analytics Tool
• Proprietary CMI Repository of Market Data (covering past 8 years)
• CMI Expert Interviews and Transcripts (focused on PET-CT market dynamics, hospital adoption trends, and vendor evaluations)